CPT® Code 81299

MSH6 (mutS homolog 6 [E. coli]) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; known familial variants

The CPT® Code 81299 pertains to the molecular genetic testing of the MSH6 gene, specifically focusing on known familial variants. This testing is crucial for identifying specific mutations within the MSH6 gene that may increase an individual's risk of developing hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome. The MSH6 gene is located on chromosome 2 and plays a vital role in the DNA repair process. It is part of a protein complex that works alongside the MSH1/PMS2 complex to detect and repair errors that occur during DNA replication. When these errors are not corrected, they can accumulate over time, leading to uncontrolled cell growth and the formation of tumors. HNPCC is the most prevalent cancer associated with mutations in the MSH6 gene, but it is important to note that tumors can also develop in various other organs, including the endometrium, ovaries, prostate, stomach, small intestine, liver, gallbladder duct, upper urinary tract, brain, and skin. Lynch syndrome is characterized by an increased risk of cancer, particularly colorectal and endometrial cancers, often presenting at an older age compared to other genetic mutations such as MLH1 and MSH2. The incidence of endometrial cancer is notably higher in individuals with MSH6 mutations. Additionally, certain mutations have been identified with increased frequency in Ashkenazi Jewish populations, with affected individuals typically experiencing the onset of tumors later in life. The testing process for MSH6 mutations involves identifying point mutations or single nucleotide polymorphisms, which are the most common types of mutations found in this gene. Furthermore, immunohistochemistry may be utilized to assess the extent of gene expression loss. Family members of individuals with identified MSH6 mutations are encouraged to undergo testing for known familial variants, and those who test positive should receive genetic counseling and clinical supervision. Overall, the analysis provided by CPT® Code 81299 is essential for understanding genetic predispositions to certain cancers and guiding appropriate clinical management.